Memphasys Felix Revenue Jumps to $111K Across Four Regions in March Quarter

Memphasys hits commercial inflection as Felix revenue scales across four regions

Memphasys Limited (ASX: MEM) has outlined the Memphasys Felix System Commercial Rollout in an investor presentation released 7 April 2026, marking the company’s transition from clinical validation to multi-region revenue generation. The March quarter delivered A$111,600 in sales revenue, a material step-change from prior quarters (June quarter nil, September quarter A$8,800, December quarter A$3,600). This revenue is not from trials or pilot programmes but from clinics using Felix in routine clinical practice, with cash received and banked.

Revenue is now generated across four regions: Europe, MENA (Middle East and North Africa), Japan, and Australia. The March quarter result reflects contributions primarily from Italy and Qatar, with repeat cartridge orders validating the consumables-driven model. Management highlighted that the commercial strategy reset implemented in late 2025 is delivering measurable outcomes, with Felix now deployed in routine workflows rather than evaluation settings.

The presentation noted that repeat orders confirm clinic adoption. This is not one-off purchasing but ongoing consumption as Felix integrates into fertility centre operations.

How electrophoresis technology is changing sperm preparation in IVF

Traditional sperm preparation methods, density gradient centrifugation and swim-up, take 30 to 60 minutes and require specialised operators. These processes are labour-intensive, introduce operator variability, and can cause DNA damage. Felix reduces processing time to approximately six minutes through electrophoresis-based selection, using a single-use cartridge and automated workflow.

Electrophoresis isolates sperm based on electrical charge, separating mature, negatively charged sperm from other cell types without mechanical or chemical stress. The technology has over 10 years of clinical validation and has been described as the first meaningful breakthrough in sperm preparation in more than 40 years.

Felix advantages over conventional methods:

• Processing time: Six minutes versus 30 to 60+ minutes
• Workflow: Single vessel, automated versus multi-step, labour-intensive
• Operator requirements: Easy to train versus requiring specialised clinical operators
• Consistency: Operator-independent versus subject to variability
• DNA integrity: Reduced damage versus increased damage with centrifugation
• Embryo utilisation: Improved rates versus lower rates with conventional methods

For fertility clinics, Felix increases lab throughput, reduces variability in outcomes, and integrates into existing IVF processes without requiring complex equipment changes. The company’s presentation stated that Felix results in better clinical outcomes compared to density gradient centrifugation and is the preferred method over such techniques.

Contracted revenue agreements underpin near-term growth

Memphasys has secured commercial supply agreements across multiple regions, providing contracted revenue pathways and repeat ordering behaviour. These agreements are not trials or pilot programmes but active commercial supply arrangements.

Regional commercial agreements:

1. Italy (CFA Italia): Multi-year commercial supply agreement with approximately A$925,000 minimum contracted value. Clinic onboarding is underway following CE Mark approval in December 2025.

2. MENA (ITL): Exclusive five-year commercial supply agreement with approximately A$390,000 minimum contracted value. Qatar’s Hamad Medical Corporation placed initial cartridge orders in December 2025 and secured repeat orders in February 2026, validating commercial execution. Expansion is underway across Qatar, UAE, and broader Gulf markets, with sales across six countries reported.

3. Japan: First commercial Felix orders occurred in August 2023, with ongoing repeat cartridge orders establishing Japan as a high-quality reference market.

4. India (ACC): Non-exclusive five-year supply agreement signed in October 2025, pending CDSCO (Central Drugs Standard Control Organisation) approval, expected within approximately six months. Year 1 minimum: 1,800 cartridges (approximately A$98,800 revenue), with delivery cadence of 450 cartridges per quarter. Year 2 minimum: at least 2,700 cartridges, representing minimum 50% growth.

5. Australia and New Zealand: Advanced contractual discussions are underway for near-term commercialisation following TGA (Therapeutic Goods Administration) approval.

The presentation emphasised that contracted minimums provide revenue visibility, while repeat ordering behaviour validates the recurring revenue model inherent in the consumables-driven platform.

Unit economics point to margin expansion

Felix operates on a two-part model: console placement enables clinic onboarding, while single-use cartridges drive recurring revenue. One cartridge is used per IVF procedure, meaning revenue scales directly with procedure volumes rather than requiring continuous new customer acquisition.

Target cartridge pricing: A$80 to A$150 per cartridge
Target cost of goods sold (COGS): Below A$40 per cartridge
Gross margin potential: 60%+ as scale increases

Management stated the company is constantly looking at COGS improvements and is confident of realising the target COGS of below A$40 within the next 12 months.

Clinic-level economics: Each clinic is positioned to generate A$100,000 to A$300,000 in annual revenue, tied to procedure volume rather than capital equipment sales. The consumables model creates minimal incremental cost per procedure, enabling margin expansion as the installed base grows.

Marjan Mikel, Director

“Felix is a consumables-driven platform with strong repeat purchasing behaviour. Revenue scales with clinic throughput.”

The presentation described this as an accretive multi-year recurring revenue model for every clinic, with operating leverage built into the commercial structure.

Regulatory approvals now accelerating rather than gating rollout

Regulatory clearances have transitioned from a development hurdle to a commercial enabler. Felix has secured approvals across multiple high-regulatory jurisdictions, with CE Mark recognition supporting rapid expansion into additional markets.

Approved and commercially accessible markets:

• Europe: CE Mark approved (EU MDR 2017/745), enabling immediate commercial access
• Australia: TGA approved, validating entry into a high-regulatory market
• United Kingdom: MHRA (Medicines and Healthcare products Regulatory Agency) registered
• Japan: No regulatory hurdles, with ongoing commercial sales since 2023
• Canada: No regulatory hurdles

Regulatory leverage for expansion:

The CE Mark supports rapid entry into MENA and Asia-Pacific markets. India’s CDSCO submission has been lodged, with completion expected within approximately six months. The presentation stated that regulatory approvals are no longer a gating factor but are now accelerating commercial rollout across multiple jurisdictions simultaneously.

Near-term catalysts over the next six months

Management outlined several parallel workstreams expected to deliver news flow over the next two quarters:

• India regulatory completion (CDSCO approval expected within approximately six months)
• European, MENA, and APAC scaling (clinic onboarding and cartridge supply expansion)
• ANZ commercialisation (advanced contractual discussions underway following TGA approval)
• COGS improvements (described as “very advanced” in the presentation)
• Reseller expansion (onboarding partners with existing IVF/ART distribution capability)
• Recurring revenue growth (driven by increased procedure volumes across the installed base)

The presentation noted that multiple parallel initiatives provide potential for material updates across different regions and milestones over the coming quarters.

Investment case for Memphasys

Memphasys has transitioned from research and development to revenue-generating commercial operations, with Felix now used in routine clinical workflows across four regions. The company addresses a global fertility market projected to grow from US$36 billion in 2024 to US$85 billion by 2034, representing a 9% compound annual growth rate. Male factor infertility accounts for approximately 50% of fertility issues, yet sperm preparation technology has seen minimal innovation for over 40 years.

The presentation highlighted that 1 in 6 couples experience fertility issues, with sperm dysfunction the single most common cause. Global fertility rates are declining, with male sperm quality deteriorating, creating structural demand for improved processing technologies.

Felix operates on a recurring consumables revenue model, with contracted supply agreements and demonstrated repeat ordering behaviour across Japan, Italy, Qatar, and broader MENA markets. Each clinic represents A$100,000 to A$300,000 in potential annual revenue, with 60%+ gross margin potential as scale increases.

Regulatory approvals across Europe, Australia, UK, Japan, and Canada provide immediate market access, with CE Mark recognition enabling rapid expansion into MENA and APAC jurisdictions. India’s CDSCO approval is expected within approximately six months, unlocking a large near-term market with contracted supply agreements already in place.

The company’s commercial strategy focuses on direct clinic engagement and distribution partnerships with existing IVF/ART capabilities, targeting high-value, regulator-ready markets. The shift from validation to revenue generation represents a material de-risking of the platform, with repeat cartridge orders confirming that Felix is being integrated into routine practice rather than remaining in evaluation.

Don’t Miss the Next Healthcare Breakthrough

Join 20,000+ investors getting FREE breaking ASX news delivered to your inbox within minutes of release, complete with in-depth analysis. Click the “Free Alerts” button at StockWire X to start receiving alerts the moment market-moving announcements break across the Healthcare sector.